Cargando…

Systematic Analysis of Cellular Signaling Pathways and Therapeutic Targets for SLC45A3:ERG Fusion-Positive Prostate Cancer

ETS-related gene (ERG) fusion affects prostate cancer depending on the degree of expression of ERG. Solute Carrier Family 45 Member 3 (SLC45A3) is the second-most common 5′ partner gene of ERG rearrangement. However, the molecular pathological features of SLC45A3:ERG (S:E) fusion and therapeutic met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jongsu, Hwang, Kyung Won, Lee, Hye Jung, Kim, Hong Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693845/ https://www.ncbi.nlm.nih.gov/pubmed/36579559 http://dx.doi.org/10.3390/jpm12111818

Ejemplares similares

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer
por: Yun, Jae Won, et al.
Publicado: (2021)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
por: Lorenzin, Francesca, et al.
Publicado: (2022)

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients
por: Abdel-Hady, Ahmed, et al.
Publicado: (2017)

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
por: Dubovenko, Alexey, et al.
Publicado: (2015)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
por: Hernández-Llodrà, Silvia, et al.
Publicado: (2017)

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

ERG Immunohistochemistry as an Endothelial Marker for Assessing Lymphovascular Invasion
por: Kim, Sehun, et al.
Publicado: (2013)

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors
por: Geybels, Milan S., et al.
Publicado: (2015)

Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer
por: Kluth, Martina, et al.
Publicado: (2015)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer
por: Dadhania, Vipulkumar, et al.
Publicado: (2022)

TMPRSS2-ERG Gene Fusions induce prostate tumorigenesis through modulating microRNA miR-200c
por: Kim, Jung, et al.
Publicado: (2013)

Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis
por: Song, Chunjiao, et al.
Publicado: (2018)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion
por: Shin, Ye Ji, et al.
Publicado: (2022)

Celastrol Suppresses Tumor Cell Growth through Targeting an AR-ERG-NF-κB Pathway in TMPRSS2/ERG Fusion Gene Expressing Prostate Cancer
por: Shao, Longjiang, et al.
Publicado: (2013)

Erratum: Correction of Acknowledgments. ERG Immunohistochemistry as an Endothelial Marker for Assessing Lymphovascular Invasion
por: Kim, Sehun, et al.
Publicado: (2013)

ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
por: Kacprzyk, Lukasz A., et al.
Publicado: (2013)

Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies
por: Hwang, Kyung Won, et al.
Publicado: (2023)

Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer
por: Xu, Zhenyu, et al.
Publicado: (2018)

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
por: Bauer, Simone, et al.
Publicado: (2021)

Identification of F-Box/SPRY Domain-Containing Protein 1 (FBXO45) as a Prognostic Biomarker for TMPRSS2–ERG-Positive Primary Prostate Cancers
por: von Danwitz, Marthe, et al.
Publicado: (2023)

Mutation spectrum of the TYR and SLC45A2 genes in patients with oculocutaneous albinism
por: KO, JUNG MIN, et al.
Publicado: (2012)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

ERG Immunohistochemistry and Clinicopathologic Characteristics in Korean Prostate Adenocarcinoma Patients
por: Suh, Ja Hee, et al.
Publicado: (2012)

Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth
por: Obinata, Daisuke, et al.
Publicado: (2014)

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
por: Brandi, Franziska, et al.
Publicado: (2018)

Association between TMPRSS2:ERG fusion gene and the prostate cancer: systematic review and meta-analysis
por: García-Perdomo, Herney Andrés, et al.
Publicado: (2018)

TMPRSS2‐ERG fusions linked to prostate cancer racial health disparities: A focus on Africa
por: Blackburn, James, et al.
Publicado: (2019)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
por: Nam, R K, et al.
Publicado: (2007)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
por: Barwick, B G, et al.
Publicado: (2010)

Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer
por: Rye, Morten Beck, et al.
Publicado: (2014)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_84b1snpcp182efv0svp08udm62